secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mereo BioPharma Group plc (MREO)
CIK:        0001719714
Form:       8-K
Filed at:   2025-12-29T23:59:59+00:00
Accession:  0001193125-25-332520
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mereo setrusumab Phase 3 trials miss primary fracture endpoints; BMD improvements seen
--------------------------------------------------------------------------------

- Neither ORBIT (placebo) nor COSMIC (bisphosphonate) achieved statistical significance on annualized clinical fracture rate.
- Both studies met secondary endpoint of bone mineral density (BMD) improvements with strong statistical significance.
- Cash balance $48.7M at Q3 2025; company reducing pre-commercial and manufacturing costs.
- Additional analyses underway; management cites low placebo fracture rate in ORBIT.
- Continued partnering discussions for alvelestat; pipeline programs with partners remain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719714/000119312525332520/0001193125-25-332520-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719714/000119312525332520/mreo-20251229.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-332520

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer